Nafisa Ahmed

Nafisa Ahmed

Auto-generated profile, based on publicly available information

Nafisa Ahmed

Department of Mathematics & Natural Sciences, School of Data and Sciences, BRAC University, Dhaka, Bangladesh

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Current Microbiology
Verified
Journal Article
Closed access
PDF file
NANafisa Ahmed
Nafisa Ahmed
MMMaiesha Samiha Mahmood
Maiesha Samiha Mahmood
AUAsad Ullah
Asad Ullah
Yusha ArafYusha Araf
Yusha Araf
Tanjim Ishraq RahamanTanjim Ishraq Rahaman
Tanjim Ishraq Rahaman
MHMohammad Jakir Hosen
Mohammad Jakir Hosen

31 August 2022 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
MKMushira Khanam
Mushira Khanam
AMAbu Tayab Moin
Abu Tayab Moin
Kazi Ahsan AhmedKazi Ahsan Ahmed
Kazi Ahsan Ahmed
RPRajesh B. Patil
Rajesh B. Patil
AKAbul Bashar Ripon Khalipha
Abul Bashar Ripon Khalipha
BRBashudev Rudra
Bashudev Rudra
Hepatocellular carcinoma (HCC) is the most common malignant condition of the liver that occurs as a result of uncontrolled cellular proliferation after a series of disruptions at cell cycle regulatory checkpoints in the normal cell. Due to the lack of appropriate therapeutics or remedial treatment methods, new treatment strategies against HCC need to be developed. Cyclin dependent kinases (CDKs) are required to control the cell cycle and apoptosis, but their overexpressionis critical in the progression of cancer and is often expressed in HCC. Thus, CDKs are considered a promising class of target-defined therapy for HCC. Milciclib is a potential candidate for HCC which exhibits inhibitory activity against CDK2 leading to cell cycle arrest and apoptosis of tumor cells. Herein, we have halogenated the parent drug milciclib to improve its efficacy against CDK2. The primary structure of milciclib (D) was modified with F, Cl and,CF3 groups. The frontier molecular orbital features, binding affinity, non-bonded interaction and the pharmacokinetic parameters were analyzed for milciclib and its derivatives. We also performed molecular docking and extended molecular dynamics simulation studies to study the binding interactions and binding affinity more closely. Our computational investigation showed the derivatives D-F and D-CF3 have significant chemical reactivity, the best binding affinity, nonbonding interactions, and improved pharmacokinetic properties compared to the parent drug milciclib. Molecular dynamics analysis and MM-PBSA calculations indicated that D-Cl had a slightly more stable conformation and higher binding affinity compared to D-CF3.

1 September 2021 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
AMAbu Tayab Moin
Abu Tayab Moin
BSBishajit Sarkar
Bishajit Sarkar
AUAsad Ullah
Asad Ullah
Yusha ArafYusha Araf
Yusha Araf
NANafisa Ahmed
Nafisa Ahmed
BRBashudev Rudra
Bashudev Rudra
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein which is involved in cell signaling, proliferation, maturation, and movement, all of which are crucial for the proper development of cells and tissues. Cleavage of the EpCAM protein leads to the up-regulation of c-myc, e-fabp, and cyclins A and E which promote tumorigenesis. EpCAM can act as potential diagnostic and prognostic biomarker for different types of cancers as it is also found to be expressed in epithelia and epithelial-derived neoplasms. Hence, we aimed to analyze the EpCAM gene expression and any associated feedback in the patients of two major types of lung cancer (LC) i.e., lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), based on the publicly available online databases. In this study, server-based gene expression analysis represents the up-regulation of EpCAM in both LUAD and LUSC subtypes as compared to the corresponding normal tissues. Besides, the histological sections revealed the over-expression of EpCAM protein in cancerous tissues by depicting strong staining signals. Furthermore, mutation analysis suggested missense as the predominant type of mutation both in LUAD and LUSC in the EpCAM gene. A significant correlation (P-value < 0.05) between the higher EpCAM expression and lower patient survival was also found in this study. Finally, the co-expressed genes were identified with their ontological features and signaling pathways associated in LC development. The overall study suggests EpCAM to be a significant biomarker for human LC prognosis.

8 August 2024 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
NANafisa Ahmed
Nafisa Ahmed
AIAriful Islam
Ariful Islam
MHM. Mahboob Hossain
M. Mahboob Hossain
YKYearul Kabir
Yearul Kabir